DelParigi Angelo, Tschöp Matthias, Heiman Mark L, Salbe Arline D, Vozarova Barbora, Sell Susan M, Bunt Joy C, Tataranni P Antonio
Clinical Diabetes and Nutrition Section, National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona 85016, USA.
J Clin Endocrinol Metab. 2002 Dec;87(12):5461-4. doi: 10.1210/jc.2002-020871.
Prader-Willi syndrome (PWS) is a genetic disorder occurring in 1 of 10,000-16,000 live births and is characterized by excessive appetite with progressive massive obesity as well as short stature and mental retardation. Most patients have GH deficiency and hypogonadotropic hypogonadism. The causes of the hyperphagia and abnormal GH secretion are unknown. To determine whether ghrelin, a novel GH secretagogue with orexigenic properties, is elevated in PWS, we measured fasting plasma ghrelin concentration; body composition (dual-energy x-ray absorptiometry); and subjective ratings of hunger (visual analog scale) in seven subjects (6 males and 1 female; age, 26 +/- 7 yr; body fat, 39 +/- 11%, mean +/- SD) with PWS (diagnosis confirmed by genetic test) and 30 healthy subjects (reference population, 15 males and 15 females; age, 32 +/- 7 yr; body fat, 36 +/- 11%) fasted overnight. All subjects were weight stable for at least 6 months before admission to the study. The mean plasma ghrelin concentration was higher in PWS than in the reference population (307 +/- 164 vs. 109 +/- 24 fmol/ml; P < 0.001), and this difference remained significant after adjustment for percentage body fat (P < 0.001). Plasma ghrelin was also higher (P = 0.0004) in PWS than in five healthy subjects fasted for 36 h. A positive correlation was found between plasma ghrelin and subjective ratings of hunger (r = 0.71; P = 0.008). Furthermore, in subjects with PWS, the concentration of the hormone was not different before and after ingestion of 2 ml and a satiating amount of the same liquid meal (ghrelin concentrations: 307 +/- 164 vs. 306 +/- 205 vs. 260 +/- 134 fmol/ml, respectively; ANOVA for repeated measures, P = 0.56). This is the first evidence that ghrelin, a novel orexigenic hormone, is elevated in subjects with PWS. Our finding suggests that ghrelin may be responsible, at least in part, for the hyperphagia observed in PWS.
普拉德-威利综合征(PWS)是一种遗传性疾病,在10000至16000例活产婴儿中发生率为1例,其特征为食欲亢进并伴有进行性重度肥胖,以及身材矮小和智力发育迟缓。大多数患者存在生长激素(GH)缺乏和低促性腺激素性性腺功能减退。食欲亢进和GH分泌异常的原因尚不清楚。为了确定胃饥饿素(一种具有促食欲特性的新型GH促分泌素)在PWS患者中是否升高,我们测量了7例经基因检测确诊为PWS的患者(6例男性和1例女性;年龄26±7岁;体脂39±11%,均值±标准差)和30例健康受试者(参照人群,15例男性和15例女性;年龄32±7岁;体脂36±11%)过夜禁食后的空腹血浆胃饥饿素浓度、身体成分(双能X线吸收法)以及饥饿的主观评分(视觉模拟量表)。所有受试者在进入研究前体重至少稳定6个月。PWS患者的平均血浆胃饥饿素浓度高于参照人群(307±164对109±24 fmol/ml;P<0.001),在调整体脂百分比后,这种差异仍然显著(P<0.001)。PWS患者的血浆胃饥饿素也高于5例禁食36小时的健康受试者(P=0.0004)。血浆胃饥饿素与饥饿主观评分之间存在正相关(r=0.71;P=0.008)。此外,在PWS患者中,摄入2 ml及足量的同一种流食前后,该激素的浓度没有差异(胃饥饿素浓度分别为:307±164对306±205对260±134 fmol/ml;重复测量方差分析,P=0.56)。这是胃饥饿素(一种新型促食欲激素)在PWS患者中升高的首个证据。我们的发现表明,胃饥饿素可能至少部分地导致了PWS患者出现的食欲亢进。